Product Overview

Glypride 1 mg is a prescription oral antidiabetic medication manufactured by Sun Pharmaceutical Industries Ltd. It is formulated to improve glycemic control in adults with type 2 diabetes mellitus when diet and exercise alone are insufficient. The product is supplied in strips containing ten tablets, each tablet delivering a precise 1 mg dose of glimepiride. Pack sizes of 60, 90, and 120 tablets are available to support long‑term therapy. Delivery typically occurs within six to fifteen days after order placement.

What is Glypride 1 mg (Glimepiride)

Glypride belongs to the sulfonylurea class of drugs, which lower blood glucose by stimulating pancreatic beta cells to release insulin. The active ingredient, glimepiride, is chemically designated as N‑[5‑[(4‑amino‑3‑pyridyl)carbamoyl]‑2‑hydroxy‑3‑(4‑methylphenyl)‑1‑propyl]‑2‑pyridinecarboxamide. Although the manufacturer lists the active ingredient as “nan,” the approved formulation contains glimepiride 1 mg per tablet, the standard strength for this indication. This medication is indicated for patients with type 2 diabetes who require additional pharmacologic support beyond lifestyle modification.

Uses and Benefits

The primary use of Glypride is to reduce fasting and postprandial glucose levels in conjunction with a proper diet and regular physical activity. Clinical studies have demonstrated that consistent use can achieve a reduction in HbA1c of approximately 0.5 to 1.0 percent when used as monotherapy or in combination with metformin or insulin. Benefits include improved glycemic stability, decreased risk of hyperglycemic episodes, and potential preservation of beta‑cell function when used early in the disease course. Additionally, the tablet formulation offers convenience with once‑daily dosing, supporting adherence to treatment regimens.

How It Works

Glimepiride exerts its hypoglycemic effect by binding to the sulfonylurea receptor (SUR1) on the surface of pancreatic beta cells. This interaction closes ATP‑sensitive potassium channels, leading to depolarization of the cell membrane and subsequent calcium influx, which triggers insulin secretion. The released insulin enhances peripheral glucose uptake and suppresses hepatic glucose production. Because the drug’s action is dependent on the presence of functional beta cells, it is most effective in patients with residual insulin secretory capacity. The pharmacokinetic profile features a rapid onset of action within one to two hours and a duration of effect lasting approximately 12 to 24 hours, allowing for once‑daily administration.

Dosage Guidelines

Treatment should be initiated at a dose of 1 mg taken orally once daily, preferably with breakfast or the first main meal of the day. The dose may be titrated upward in increments of 1 mg at intervals of 1 to 2 weeks, based on glycemic response and tolerability, up to a maximum daily dose of 8 mg. Adjustments are recommended in patients with renal impairment or those over the age of 65, who may require lower starting doses to mitigate the risk of hypoglycemia. It is essential that patients monitor blood glucose regularly and consult their healthcare provider before making any dosage changes.

Side Effects

Like all medications, Glypride can be associated with adverse reactions. The most commonly reported side effects include hypoglycemia, dizziness, headache, and gastrointestinal discomfort such as nausea. Less frequent but clinically significant events comprise skin rashes, pruritus, and rare instances of hepatic enzyme elevation. Patients should be instructed to recognize early signs of low blood sugar, such as sweating, tremors, or confusion, and to treat episodes promptly with glucose‑containing carbohydrates. If severe or persistent side effects occur, medical attention should be sought.

Warnings and Precautions

Glypride is contraindicated in individuals with type 1 diabetes, diabetic ketoacidosis, or a history of hypersensitivity to glimepiride or any component of the formulation. Caution is advised in patients with moderate to severe hepatic impairment, adrenal insufficiency, or those undergoing procedures that may affect fasting status. Concomitant use with certain medications, such as certain beta‑blockers or over‑the‑counter cold remedies containing alcohol, may potentiate hypoglycemia. Pregnant and lactating women should only use this medication under the supervision of a qualified healthcare professional. For comprehensive safety information, refer to the FDA prescribing information.

Frequently Asked Questions

1. What is the typical starting dose of Glypride? The usual initial dose is 1 mg taken once daily with the first main meal; dosage may be increased gradually based on blood glucose response.
2. Can Glypride be used together with insulin? Yes, it may be combined with insulin therapy, but clinicians must monitor blood glucose closely to avoid hypoglycemia.
3. How should the tablets be stored? Store the medication at room temperature, away from moisture and heat, and keep the strip sealed until ready to use.
4. Is weight gain a common side effect? Weight gain can occur as glycemic control improves, but it is generally modest and should be managed through diet and exercise.
5. Where can I find more detailed prescribing information? Detailed prescribing details are available on the MedlinePlus page dedicated to type 2 diabetes and on the Drugs.com database.

Related Products

• Famotidine 20mg (Generic)
• Omesec 20 mg (Omeprazole)
• Pantocid DSR (Pantoprazole/Domperidone)
• Famotidine 40mg (Generic)
• Famocid 20mg (Famotidine)
• Famocid 40mg (Famotidine)
• Famocid (Famotidine)
• Supatret 0.04% Gel (Tretinoin)
• Supatret 0.1% Gel (Tretinoin)
• Supatret C Gel (Clindamycin/Tretinoin)
• Supatret Gel (Tretinoin)
• Acitretin 25mg (Generic)